Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice

Author(s):

Anjali Tiku Owens, MD, shares insights into how their institution or clinic implements the Risk Evaluation and Mitigation Strategy (REMS) program for mavacamten, detailing the requirements and responsibilities of the patient in the process. Additionally, the expert draws upon their real-world experience with the cardio myosin inhibitor (CMI) in clinical practice, providing valuable perspectives on the practical application of this novel drug class.

EP: 1.Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause

EP: 2.Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment

EP: 3.Aligning With 2023 ESC Guidelines in oHCM Treatment

EP: 4.Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes

Now Viewing

Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice

EP: 1.Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause

EP: 2.Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment

EP: 3.Aligning With 2023 ESC Guidelines in oHCM Treatment

EP: 4.Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes

EP: 5.Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice